Daxxify™ (daxibotulinumtoxin-A-lanm) has been approved as an injection to temporarily improve the look of moderate to severe frown lines (glabellar lines) in adults.

• Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced approval of Daxxify by the FDA.
• Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum albumin and animal-based It is due to be available sometime in 2023.
• Daxxify contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
• Daxxify is not recommended for use in children or pregnant women.